Safety Study of AP24534 to Treat Chronic Myelogenous Leukemia (CML) and Other Hematological Malignancies

Hematologic Malignancies Clinical Trial

Official title:

A Phase 1 Dose Escalation Trial to Determine the Safety, Tolerability and Maximum Tolerated Dose of Oral AP24534 in Patients With Refractory or Advanced Chronic Myelogenous Leukemia and Other Hematologic Malignancies

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00660920
• Other study ID #: AP24534-07-101
• Status: Completed
• Phase: Phase 1
• Start date: June 2008
• Est. completion date: May 2016

Study information

• Verified date: February 2018
• Source: Takeda
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to determine the maximum tolerated dose or a recommended dose of oral AP24534 in a defined schedule in patients with refractory or advanced chronic myelogenous leukemia and other refractory hematologic malignancies.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 81
• Est. completion date: May 2016
• Est. primary completion date: May 2016
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Male or Female = 18 years old

• Diagnosed hematologic malignancy (other than lymphoma) that has relapsed or is refractory to standard care or for which no standard care is available or acceptable

• Able to give written informed consent

• ECOG performance status = 2

• BSA = 1.5 m² (first cohort only)

• Minimum life expectancy of 3 months or more

• Adequate renal function defined as serum creatinine <1.5× upper limit of normal (ULN) for institution

• Adequate hepatic function (defined as: Total bilirubin <1.5 × ULN for institution; ALT and AST <2.5 × ULN for institution [<5 X ULN if liver involvement with leukemia]; Prothrombin time <1.5 × ULN)

• Ability to comply with study procedures in the Investigator's opinion

• Adequate cardiac function defined as ejection fraction (EF) >40% by any method of the investigator's choice

• Normal QTcF interval on screening ECG evaluation, defined as QTcF of <450 ms.

• For females of childbearing potential, a negative pregnancy test must be documented prior to enrollment

• Female patients who are of childbearing potential must agree to use an effective form of contraception with their sexual partners throughout participation in this study

Exclusion Criteria:

• Have had cytotoxic chemotherapy or radiotherapy within 21 days prior to entering the study, or those who have not recovered from adverse events due to agents administered more than 28 days earlier with the exception of alopecia

• Received any other investigational agents or have received an investigational agent within 14 days of starting ponatinib

• Malabsorption syndrome or other illness which could affect oral absorption

• Significant uncontrolled cardiac disease

• Patients taking medicinal products that are known to be associated with prolongation of the QT interval on the electrocardiogram.

• Uncontrolled hypertension (Diastolic BP >100 mmHg; Systolic >150 mmHg)

• Uncontrolled intercurrent illness

• Pregnant

• Known infection with HIV

• Autologous or allogeneic stem cell transplant < 3 months prior to enrollment; any evidence of ongoing graft versus host disease (GVHD), or GVHD requiring immunosuppressive therapy

• Another primary malignancy within the past 3 years

• Any condition or illness which, in the opinion of the investigator, would compromise patient safety or interfere with the evaluation of the safety of the drug

• Patients taking medicinal products that are known to be associated with prolongation of the QT interval on the electrocardiogram

• Major surgery (with the exception of intravenous catheter placement or bone marrow biopsy) within 14 days prior to initiating ponatinib therapy

Related Conditions & MeSH terms

• Chronic Myelogenous Leukemia
• Hematologic Malignancies
• Leukemia
• Leukemia, Myelogenous, Chronic, BCR-ABL Positive
• Leukemia, Myeloid
• Neoplasms

Intervention

Drug:
• Ponatinib
Comparison of different dosages of drug given orally once per day.

Locations

Country	Name	City	State
United States	ARIAD Investigational Site #011	Ann Arbor	Michigan
United States	ARIAD Investigational Site #005	Houston	Texas
United States	ARIAD Investigational Site #076	Nashville	Tennessee
United States	ARIAD Investigational Site #048	Portland	Oregon
United States	ARIAD Investigational Site #075	San Francisco	California

Sponsors (1)

Lead Sponsor	Collaborator
Ariad Pharmaceuticals

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Determine Maximum Tolerated Dose (MTD) or Recommended dose	Determine MTD dose or a recommended dose of oral ponatinib in a defined schedule (QD) in patients with refractory or advanced chronic myelogenous leukemia and other refractory hematologic malignancies.	Up to
Secondary	To examine the safety of AP24534 in patients with resistant/refractory hematologic malignancies		Up to 7 years
Secondary	To describe the anti-tumor activity of AP24534 in patients with refractory hematologic malignancies		Up to 7 years
Secondary	To examine the pharmacokinetics of AP24534		Up to 2 cycles (1 cycle = 28 days)
Secondary	To examine pharmacodynamic activity of AP24534 in CML and Ph + ALL patients		Up to 7 years
Secondary	To describe potential pharmacogenomic markers of AP24534 anti-tumor activity		Up to 7 years